Inventiv Health — Q2 2015 Earnings Presentation
16 slides from Inventiv Health's earnings presentation, Aug 14, 2015
Slide 1: inVentiv Health Second Quarter 2015 Earnings Presentation
Exhibit 99.1 inVentiv Health Second Quarter 2015 Earnings Presentation Aug 17, 2015
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect o
Slide 3: Quarterly Highlights
Quarterly Highlights Strong financial performance in Q2 builds on recent momentum Organic revenue (1) growth of 12% (9% reported net revenue growth) Adjusted EBITDA(2) growth of 32% to $62mm Q2 benefited from timing within the year of certain items Year-to-date organic revenue (1) and Adjusted EBITD
Slide 4: Clinical Update
Clinical Update Organic Revenue (1) growth of 11% (7% reported net revenue growth) Backlog conversion accelerating on full service projects Growth is strongest in full service space Strategic resourcing revenues expected to accelerate in second half Miami clinic will come on-line in January; first s
Slide 5: Commercial Update
Commercial Update Acceleration of performance in Q2 Organic Revenue (1) growth of 13% (11% reported net revenue growth) Adjusted EBITDA(2) growth of 40% Selling solutions business strength continues Record volume of new teams launched in quarter Additional margin enhancements realized in communicati
Slide 6: Consolidated inVentiv Health Q2 2015 Financial Update
Consolidated inVentiv Health Q2 2015 Financial Update Net Revenues(1) ($ millions) $489 $940 $450 $871 Q2 2014 Q2 2015 YTD 2014 YTD 2015 Adjusted EBITDA(2) ($ millions) $62 $114 $47 $90 Q2 2014 Q2 2015 YTD 2014 YTD 2015 (1) The sum of the segments do not reconcile to Consolidated inVentiv Health due
Slide 7: Clinical Performance
Clinical Performance Net Revenues(1) ($ millions) $234 $453 $218 $433 Q2 2014 Q2 2015 YTD 2014 YTD 2015 Adjusted EBITDA(2) $56 ($ millions) $29 $47 $22 Q2 2014 Q2 2015 YTD 2014 YTD 2015 (1) The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegmen
Slide 8: Clinical Book-to-Bill
Clinical Book-to-Bill Total Clinical Q1 2015 Q2 2015 LTM Serviceable Backlog Rollforward Beginning Backlog $1,860 $1,926 $1,806 New Wins $380 $368 $1,446 Cancellations and Scope Changes, (net) ($90) ($117) ($290) Project Restart and (Delays), net ($5) ($1) ($130) Revenue Earned ($220) ($234) ($891)
Slide 9: Commercial Performance
Commercial Performance Net Revenues(1) ($ millions) $259 $493 $233 $442 Q2 2014 Q2 2015 YTD 2014 YTD 2015 Adjusted EBITDA(2) ($ millions) $42 $76 $30 $55 Q2 2014 Q2 2015 YTD 2014 YTD 2015 (1) The sum of the segments do not reconcile to Consolidated inVentiv Health due to eliminations of approximatel
Slide 10: Appendix
re Appendix -\inVentiv “ ="')Health
Slide 11: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation For the Quarter and Last Six Months Ended June 30, 2015 ($ millions) QTD QTD YTD YTD Q2 2015 Q2 2014 Q2 2015 Q2 2014 Net Income (loss) from continuing operations ($30.0) ($47.5) ($75.0) ($93.5) Income tax provision (benefit) 2.7 5.8 7.3 7.7 Interest expense, net 57.1 5
Slide 12: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation For the Quarter Ended June 30, 2015 ($ millions) inVentiv Clinical Commercial Corporate Health, Inc. Net Income (loss) from continuing operations ($30.0) Income tax provision (benefit) 2.7 Interest expense, net 57.1 Equity investment income (0.2) Operating Income $17.6
Slide 13: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation For the Quarter Ended June 30, 2014 ($ millions) inVentiv Clinical Commercial Corporate Health, Inc. Net Income (loss) from continuing operations ($47.5) Income tax provision (benefit) 5.8 Interest expense, net 53.2 Equity investment income 0.2 Operating Income $3.5 $1
Slide 14: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation For the Six Months Ended June 30, 2015 ($ millions) inVentiv Clinical Commercial Corporate Health, Inc. Net Income (loss) from continuing operations ($75.0) Income tax provision (benefit) 7.3 Interest expense, net 113.6 Equity investment income 1.3 Operating Income $32
Slide 15: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation For the Six Months Ended June 30, 2014 ($ millions) inVentiv Clinical Commercial Corporate Health, Inc. Net Income (loss) from continuing operations ($93.5) Income tax provision (benefit) 7.7 Interest expense, net 105.7 Equity investment income 0.2 Operating Income $7.
Slide 16: Adjusted EBITDA Footnotes
Adjusted EBITDA Footnotes (a) Represents non-cash losses associated with the write-off of goodwill, intangible assets and other long-lived assets that affect the comparability of our operational results and for which an adjustment is made consistent with the terms of our debt instruments. (b) Repres